Reblozyl sales surged 35% in Q1 for BMY, but a failed phase III study clouds expansion plans amid stiff anemia drug ...

Bristol-Myers Squibb Company (NYSE:BMY) is one of the stocks Jim Cramer reflected on. When asked about the stock during the ...